- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
June 23, 2022Robins Kaplan’s Antitrust Class Action Practice Recognized as Leader In The Field For Fourth Consecutive Year
-
June 17, 2022Robins Kaplan Secures Complete Dismissal of $160 Million Copyright and Software License Dispute
-
June 13, 2022Robins Kaplan Wins Judgment Vacating Two Confessions of Judgment Totaling Nearly $20 Million
-
July 25, 2022Tee It Up for the Troops
-
September 22, 202220th Annual Golf Tournament
-
June 21, 2022How To Oppose An Extension If You Really Need To
-
June 7, 2022Damned if You Do,
Damned if You Don’t -
June 7, 2022Take-Home COVID: The New Frontier?
-
June 24, 2022Biggest US Banks Sail Through Latest Round of Fed Stress Testing
-
June 23, 2022Powell Admits Recession Possible, Sees Tricky Path to Soft Landing
-
June 22, 2022Meta Reaches Settlement With Feds Over Allegedly Discriminatory Housing Ads
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
Judge Rules Collegium Pharmaceutical Inc. Does Not Infringe Two OxyContin Patents
October 1, 2018
A Massachusetts federal judge recently ruled that Robins Kaplan client Collegium Pharmaceutical Inc. did not infringe upon two of Purdue Pharma LP’s OxyContin-related patents. The ruling represents a significant victory for Collegium and its two-year-old drug, Xtampza XR.
Law360 covered the ruling in a recent article:
Xtampza Not Infringing 2 OxyContin Patents, Judge Says
All Content © 2018, Portfolio Media, Inc.
Related Professionals
Christopher A. Pinahs
Partner
Christopher P. Sullivan
Partner
Matthew P. Cardosi
Associate
Alice Mendelsohn Ribbens, Ph.D.
Senior Scientist
Related Publications
May 13, 2022
Trademark Applications and the Murky Waters of Subject Matter Jurisdiction
David Martinez, Zac Cohen - Los Angeles & San Francisco Daily Journal
April 19, 2022
Video Game Content Creators Face COPPA Liability Hazards
Matthew Woods, Austin Miller - Bloomberg Law
October 26, 2021
Simple Steps to Protecting Confidential Information in the Global Economy
David Prange - Managing IP
July 15, 2021
Biotechnology & Trade Secret Protection
Sharon Roberg-Perez, David Prange, Ellen Levish - Bloomberg Law
June 8, 2021
Written Description in the Life Sciences: The Devil is in the Details
Sharon Roberg-Perez, William Jones - IPWatchdog
Related News
June 17, 2022
June 1, 2022
February 15, 2022
Back to Top
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.